VieCure Raises $43 Million to Help Democratize Access to the Highest Caliber Cancer Care in Community Practices

• Round led by legendary business icon Mitch Rales, co-founder of Danaher, one of the world’s most successful companies, and Northpond Ventures
• Funds will accelerate the expansion of VieCure’s AI platform and its growing footprint of community oncology clinics
• VieCure is partnering with Mitch Rales’ business-building firm, New Bearing, to instill in VieCure world-class operational capabilities through the New Bearing Foundational Business System

DENVER--(BUSINESS WIRE)--VieCure, a leading provider of intelligent software platforms for oncology care, has raised $43 million in funding to accelerate its mission to democratize access to precision medicine in community cancer care practices.

The round was led by Mitch Rales, co-founder of Danaher, and Northpond Ventures, with significant participation from Durable Capital Partners, Socium Ventures – a venture firm backed by Cox Enterprises, and Sator Grove Holdings. Additionally, Mitch Rales and Howard “Skip” Burris III, M.D., a past president of the American Society of Clinical Oncology (ASCO), have joined the company’s Board of Directors.

Addressing the Growing Complexity of Cancer Care

Community oncology clinics in the U.S. treat more than 80% of cancer patients each year, yet they are increasingly overburdened by the rapidly expanding complexity of delivering care. As a result, the pace of adopting precision medicine protocols is lagging, putting both the financial stability of practices and patient outcomes at potential risk.

VieCure’s Halo Intelligence™ platform supports clinics in reducing these complexities by ensuring clinicians have real-time access to everything they need to deliver the right treatment to every patient. As an AI-powered clinical decision support and smart electronic medical record platform, Halo combines structured patient data, artificial intelligence, and workflow automation to enhance the speed and precision of clinical decision-making while reducing the operational barriers associated with delivering best-in-class care.

“This investment marks a pivotal moment in our mission to transform how cancer care is delivered to patients everywhere,” said Michael Power, CEO of VieCure. “Every day, oncologists use our platform to personalize treatment and connect patients to the right therapies at the right time. The continued partnership with Northpond Ventures and new support from Mitch Rales reflect shared conviction that technology can and should elevate human care – helping millions of people live longer, better lives.”

“VieCure is profoundly improving people’s lives, so I’m honored to join the board and, through my business-building firm, New Bearing, partner with VieCure’s talented management team to instill in VieCure the highest level of operating capabilities,” said Mitch Rales. “At New Bearing, we believe passionately in the power of compounding over decades, and this is our mindset with VieCure and everything that we do. We are committed to VieCure for the long-term.”

“As the clinical and operational backbone for cancer clinics, VieCure is democratizing access to the highest caliber cancer care in community settings,” said Michael Rubin, M.D., Ph.D., CFA, Founder and CEO of Northpond Ventures. “With an intelligent software platform designed for clinical precision and ease of use, VieCure is poised to become the largest conduit for evidence-based, guideline-informed care for cancer patients.”

Real-World Impact

Today, VieCure manages care for nearly 30,000 patients with a growing national network of practice locations. The company has demonstrated its ability to help clinics drive meaningful improvements in care delivery, including an ~8x increase in the rate of tumor sequencing, a ~2x increase in the use of guideline-compliant treatment plans, and a notable increase in oncologist capacity and workflow productivity. Practices using the VieCure platform have reported measurable improvements in operational efficiency and overall quality of care.

“The future of cancer care depends on tools that assist in day-to-day workflows and make it easier for physicians to deliver the right therapy at the right time,” said Dr. Howard A. "Skip" Burris, III, MD, FASCO, FACP, VieCure Board Member, Medical Oncologist, and past President of ASCO. “VieCure helps practices reduce clinician burden, stay aligned with evolving standards, and focus on delivering timely and appropriate care for every patient.”

“VieCure has fundamentally changed how we care for patients,” said Ashvini Sengar, M.D., President and Chief Medical Officer of Alabama Cancer Care. “Halo Intelligence™ improves coordination across our team, strengthens clinical and diagnostic decision-making, and streamlines operations – it’s become central to how we manage our business and improve the care we deliver.”

About VieCure

VieCure, a cancer care innovation company, offers a proprietary digital ecosystem, Halo Intelligence™, powered by artificial intelligence (AI) informatics, a clinical inference engine, and a purpose-built oncology electronic medical record (EMR). Halo Intelligence™ provides real-time clinical decision support by integrating patient data with evidence-based knowledge and digital workflows at the point of care, enabling oncologists to design personalized, comprehensive care plans across diagnosis, treatment, and follow-up. VieCure partners with cancer centers throughout the United States and maintains strategic alliances with Life Science organizations focused on advancing cancer care. For more information, please visit VieCure.com and connect with the company on LinkedIn.

VieCure, the VieCure logo, and Halo Intelligence are trademarks of VieCure Inc.